-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 17, Sinopharm Modern announced that its wholly-owned subsidiary Sinopharm Rongsheng's esomeprazole sodium for injection (40mg) was approved, which can be used as an alternative therapy for gastroesophageal reflux disease when oral therapy is not applicable.
It is used to reduce the risk of rebleeding after endoscopic treatment of gastric and duodenal ulcer bleeding in adults, and to prevent stress ulcer bleeding in severe patients
.
It is used to reduce the risk of rebleeding after endoscopic treatment of gastric and duodenal ulcer bleeding in adults, and to prevent stress ulcer bleeding in severe patients
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection.
It can inhibit the specific proton pump to reduce gastric acid secretion, and has a good inhibitory effect on basal gastric acid secretion and stimulated gastric acid secretion.
, Good compliance and tolerability in maintenance therapy and on-demand therapy are clinically recognized
.
It can inhibit the specific proton pump to reduce gastric acid secretion, and has a good inhibitory effect on basal gastric acid secretion and stimulated gastric acid secretion.
, Good compliance and tolerability in maintenance therapy and on-demand therapy are clinically recognized
.
Esomeprazole sodium for injection was developed by AstraZeneca.
It was first listed in Sweden in 2003, and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to the official website of the Center for Drug Evaluation of the State Food and Drug Administration , the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals will be about 3.
951 billion yuan in 2021
.
Up to now, Sinopharm Hyundai has invested about 3 million yuan in research and development expenses in the project of esomeprazole sodium for injection
.
It was first listed in Sweden in 2003, and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to the official website of the Center for Drug Evaluation of the State Food and Drug Administration , the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals will be about 3.
951 billion yuan in 2021
.
Up to now, Sinopharm Hyundai has invested about 3 million yuan in research and development expenses in the project of esomeprazole sodium for injection
.
On February 17, Sinopharm Modern announced that its wholly-owned subsidiary Sinopharm Rongsheng's esomeprazole sodium for injection (40mg) was approved, which can be used as an alternative therapy for gastroesophageal reflux disease when oral therapy is not applicable.
It is used to reduce the risk of rebleeding after endoscopic treatment of gastric and duodenal ulcer bleeding in adults, and to prevent stress ulcer bleeding in severe patients
.
It is used to reduce the risk of rebleeding after endoscopic treatment of gastric and duodenal ulcer bleeding in adults, and to prevent stress ulcer bleeding in severe patients
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection.
It can inhibit the specific proton pump to reduce gastric acid secretion, and has a good inhibitory effect on basal gastric acid secretion and stimulated gastric acid secretion.
, Good compliance and tolerability in maintenance therapy and on-demand therapy are clinically recognized
.
It can inhibit the specific proton pump to reduce gastric acid secretion, and has a good inhibitory effect on basal gastric acid secretion and stimulated gastric acid secretion.
, Good compliance and tolerability in maintenance therapy and on-demand therapy are clinically recognized
.
Esomeprazole sodium for injection was developed by AstraZeneca.
It was first listed in Sweden in 2003, and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to the official website of the Center for Drug Evaluation of the State Food and Drug Administration , the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals will be about 3.
951 billion yuan in 2021
.
Up to now, Sinopharm Hyundai has invested about 3 million yuan in research and development expenses in the project of esomeprazole sodium for injection
.
It was first listed in Sweden in 2003, and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to the official website of the Center for Drug Evaluation of the State Food and Drug Administration , the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals will be about 3.
951 billion yuan in 2021
.
Up to now, Sinopharm Hyundai has invested about 3 million yuan in research and development expenses in the project of esomeprazole sodium for injection
.
On February 17, Sinopharm Modern announced that its wholly-owned subsidiary Sinopharm Rongsheng's esomeprazole sodium for injection (40mg) was approved, which can be used as an alternative therapy for gastroesophageal reflux disease when oral therapy is not applicable.
It is used to reduce the risk of rebleeding after endoscopic treatment of gastric and duodenal ulcer bleeding in adults, and to prevent stress ulcer bleeding in severe patients
.
It is used to reduce the risk of rebleeding after endoscopic treatment of gastric and duodenal ulcer bleeding in adults, and to prevent stress ulcer bleeding in severe patients
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection.
It can inhibit the specific proton pump to reduce gastric acid secretion, and has a good inhibitory effect on basal gastric acid secretion and stimulated gastric acid secretion.
, Good compliance and tolerability in maintenance therapy and on-demand therapy are clinically recognized
.
It can inhibit the specific proton pump to reduce gastric acid secretion, and has a good inhibitory effect on basal gastric acid secretion and stimulated gastric acid secretion.
, Good compliance and tolerability in maintenance therapy and on-demand therapy are clinically recognized
.
Esomeprazole sodium for injection was developed by AstraZeneca.
It was first listed in Sweden in 2003, and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to the official website of the Center for Drug Evaluation of the State Food and Drug Administration , the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals will be about 3.
951 billion yuan in 2021
.
Up to now, Sinopharm Hyundai has invested about 3 million yuan in research and development expenses in the project of esomeprazole sodium for injection
.
Pharmaceuticals , pharmaceutical companies , companies , companies , hospitals , hospitals, hospitals It was first listed in Sweden in 2003, and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to the official website of the Center for Drug Evaluation of the State Food and Drug Administration , the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals will be about 3.
951 billion yuan in 2021
.
Up to now, Sinopharm Hyundai has invested about 3 million yuan in research and development expenses in the project of esomeprazole sodium for injection
.
